JP2020512336A5 - - Google Patents

Download PDF

Info

Publication number
JP2020512336A5
JP2020512336A5 JP2019552871A JP2019552871A JP2020512336A5 JP 2020512336 A5 JP2020512336 A5 JP 2020512336A5 JP 2019552871 A JP2019552871 A JP 2019552871A JP 2019552871 A JP2019552871 A JP 2019552871A JP 2020512336 A5 JP2020512336 A5 JP 2020512336A5
Authority
JP
Japan
Prior art keywords
amino acid
compound
zero
use according
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019552871A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020512336A (ja
JP7719590B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/AU2018/050295 external-priority patent/WO2018176099A1/en
Publication of JP2020512336A publication Critical patent/JP2020512336A/ja
Publication of JP2020512336A5 publication Critical patent/JP2020512336A5/ja
Priority to JP2023034511A priority Critical patent/JP7795489B2/ja
Application granted granted Critical
Publication of JP7719590B2 publication Critical patent/JP7719590B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019552871A 2017-03-31 2018-03-29 Tlrアゴニストによる呼吸器感染症の治療 Active JP7719590B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023034511A JP7795489B2 (ja) 2017-03-31 2023-03-07 Tlrアゴニストによる呼吸器感染症の治療

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
AU2017901180 2017-03-31
AU2017901180A AU2017901180A0 (en) 2017-03-31 Treatment of respiratory infection
AU2017905124 2017-12-21
AU2017905124A AU2017905124A0 (en) 2017-12-21 Treatment of respiratory infection (2)
AU2017905128 2017-12-21
AU2017905128A AU2017905128A0 (en) 2017-12-21 Optimised compounds
AU2018900409A AU2018900409A0 (en) 2018-02-09 Treatment of respiratory infection (3)
AU2018900409 2018-02-09
PCT/AU2018/050295 WO2018176099A1 (en) 2017-03-31 2018-03-29 Treatment of respiratory infection with a tlr2 agonist

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023034511A Division JP7795489B2 (ja) 2017-03-31 2023-03-07 Tlrアゴニストによる呼吸器感染症の治療

Publications (3)

Publication Number Publication Date
JP2020512336A JP2020512336A (ja) 2020-04-23
JP2020512336A5 true JP2020512336A5 (https=) 2021-04-08
JP7719590B2 JP7719590B2 (ja) 2025-08-06

Family

ID=63673872

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019552871A Active JP7719590B2 (ja) 2017-03-31 2018-03-29 Tlrアゴニストによる呼吸器感染症の治療
JP2023034511A Active JP7795489B2 (ja) 2017-03-31 2023-03-07 Tlrアゴニストによる呼吸器感染症の治療

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023034511A Active JP7795489B2 (ja) 2017-03-31 2023-03-07 Tlrアゴニストによる呼吸器感染症の治療

Country Status (8)

Country Link
US (1) US20200147028A1 (https=)
EP (1) EP3600374B1 (https=)
JP (2) JP7719590B2 (https=)
CN (2) CN110461351B (https=)
AU (1) AU2018241248B2 (https=)
ES (1) ES2979287T3 (https=)
PL (1) PL3600374T3 (https=)
WO (1) WO2018176099A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2618842T3 (da) 2010-09-22 2019-07-01 Ena Therapeutics Pty Ltd Hidtil ukendt immunstimulerende fremgangsmåde
EP3728289B1 (en) 2017-12-21 2025-09-10 Axelia Oncology Pty Ltd Optimised compounds
US20210177795A1 (en) * 2017-12-21 2021-06-17 Ena Therapeutics Pty Ltd Administering compounds
KR20220050873A (ko) * 2019-06-26 2022-04-25 악셀리아 온콜로지 피티와이 리미티드 신규한 분자
WO2021042171A1 (en) * 2019-09-04 2021-03-11 Ena Therapeutics Pty Ltd Cancer immunotherapy
US20220347146A1 (en) * 2019-09-04 2022-11-03 Axelia Oncology Pty Ltd Cancer treatment
US20230346829A1 (en) * 2020-05-11 2023-11-02 Revir, Inc. Compositions and methods for treating viral infections
EP4157255A4 (en) * 2020-05-26 2024-07-03 Ena Respiratory Pty Ltd CORONAVIRUS TREATMENT
WO2021258154A1 (en) * 2020-06-26 2021-12-30 Axelia Oncology Pty Ltd Branched lipid compounds
US20240358822A1 (en) * 2021-08-31 2024-10-31 Ena Respiratory Pty Ltd Allergy treatment
EP4395762A1 (en) * 2021-09-02 2024-07-10 Ena Respiratory Pty Ltd Formulation
CN114539356B (zh) * 2022-02-21 2023-06-09 中国人民解放军陆军军医大学 一种脂肽及其制备方法和应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4119856A1 (de) 1991-06-17 1992-12-24 Hoechst Ag N-acyl-s-(2-hydroxyalkyl)-cysteine, deren herstellung sowie deren verwendung als zwischenprodukte zur herstellung von synthetischen immunadjuvantien und synthetischen impfstoffen
US7723303B2 (en) * 2000-08-24 2010-05-25 The Regents Of The University Of California Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response
WO2003090682A2 (en) * 2002-04-25 2003-11-06 The Scripps Research Institute Treatment and prevention of pulmonary conditions
WO2005079419A2 (en) 2004-02-17 2005-09-01 The Regents Of The University Of California Methods of treating immunopathological disorders
WO2005115430A1 (en) * 2004-05-27 2005-12-08 Gropep Limited Treatment of inflammatory airway disease
WO2009137103A2 (en) * 2008-05-09 2009-11-12 Ourth Donald D Anti-cancer/anti-viral compounds and methods of use
WO2010115229A1 (en) 2009-04-09 2010-10-14 The University Of Melbourne Immunogenic composition and uses thereof
AU2011232421B2 (en) * 2010-03-23 2015-08-13 Novartis Ag Compounds (cystein based lipopeptides) and compositions as TLR2 agonists used for treating infections, inflammations, respiratory diseases etc.
DK2618842T3 (da) * 2010-09-22 2019-07-01 Ena Therapeutics Pty Ltd Hidtil ukendt immunstimulerende fremgangsmåde
JP6240077B2 (ja) * 2011-10-06 2017-11-29 イムノバクシーン・テクノロジーズ・インコーポレイテッドImmunovaccine Technologies Inc. Tlr2を活性化するか、またはその活性を増加させるアジュバントを含むリポソーム組成物およびその使用
WO2016037240A1 (en) * 2014-09-12 2016-03-17 The University Of Melbourne Immunological reagent

Similar Documents

Publication Publication Date Title
JP2020512336A5 (https=)
JP7795489B2 (ja) Tlrアゴニストによる呼吸器感染症の治療
JP2023081969A5 (https=)
JP2010502738A (ja) ナトリウムチャネル遮断剤および浸透圧調節物質での処置により粘膜水和および粘膜クリアランスを増強する方法
CN108350022A (zh) 聚乙二醇缀合的糖皮质激素前体药物及其组合物和方法
US20200323882A1 (en) Phlip®-mediated targeting of corticosteroids to diseased tissue
US10258634B2 (en) Ciclesonide for the treatment of airway disease in horses
AU2018370019A1 (en) Stable compositions of pegylated carfilzomib compounds
CN106488770A (zh) 用于治疗copd的福莫特罗和布地奈德的组合
JP4959919B2 (ja) 官能基を有するポリエチレングリコール賦形剤を用いた医薬用エアロゾル組成物
RU2010137337A (ru) Способы и композиции для лечения респираторных заболеваний
JP2007512223A5 (https=)
JP2010215527A (ja) 慢性閉塞性肺疾患改善剤
JP7254130B2 (ja) 結晶多形および医薬組成物
US20160331839A1 (en) Method for increasing the bioavailability of inhaled compounds
CN114144195A (zh) 血管活性肠肽(vip)用于治疗药源性肺炎的用途
RU2013116520A (ru) Гиперсульфатированные дисахариды для лечения нарушений, связанных с эластазой
JP6021952B2 (ja) 慢性閉塞性肺疾患の治療法
RU2504382C1 (ru) Ингаляционный препарат для лечения бронхиальной астмы и хронической обструктивной болезни легких и способ его получения
RU2494730C1 (ru) Ингаляционный препарат для лечения болезней органов дыхания, содержащий в качестве активных веществ микронизированный салметерол ксинофоат и микронизированный флутиказона пропионат и способ его получения
AU2022332283A1 (en) Compositions and methods for treating and preventing lung disease
HK1246147B (zh) 聚乙二醇基肾上腺髓质素前药及其用途
KR20060118509A (ko) 신규 화합물
TH1901007253A (th) บิส-ออกทาไฮโดรฟีแนนทรีนคาร์บอนซาไมด์ และโปรตีนคอนจูเกตของสิ่งเหล่านั้น
HK1246147A1 (zh) 聚乙二醇基肾上腺髓质素前药及其用途